Company intelligence / Profile preview

Biopharmartis

Lausanne, Vaud, Switzerland

Ownership: Private
Development stage: Other

Overview

Biopharmartis is a biotechnology company focused on the discovery and development of next-generation therapeutic antibodies for oncology and hematology. The company utilizes its proprietary B-Body platform to engineer multi-specific antibodies with enhanced binding properties and therapeutic efficacy. Their current research efforts are centered on targeting well-validated pathways such as CD38 and the PD-1/PD-L1 axis to address unmet needs in multiple myeloma and various solid tumors. Biopharmartis aims to advance its lead candidates through pre-clinical validation toward clinical-stage development.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Beyond the preview

Go deeper on Biopharmartis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biopharmartis.

Explore the full profile